<DOC>
	<DOC>NCT00072709</DOC>
	<brief_summary>This is a global multicenter study designed to evaluate the safety and clinical effects of 4 oral doses of TCH346 (1.0, 2.5, 7.5, and 15 mg) compared to placebo in patients with mild or mild to moderate stages of ALS. The study consists of 3 phases: screening (up to 2 weeks), run-in (16 weeks), and a double-blind treatment phase of variable duration (at least 24 weeks).</brief_summary>
	<brief_title>Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS)</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Inclusion criteria: clinical diagnosis of laboratorysupported probable, probable, or definite ALS; sporadic or familial ALS; ALS symptom onset for no more than 3 yrs at study entry; FVC equal to or more than 70%; patients who are either riluzole naive or patients who are receiving concomitant treatment with riluzole at a stable dose of riluzole (50 mg bid) at study start. Exclusion criteria: Known or suspected chronic infectious disease including HIV, hepatitis B, or hepatitis C. Clinically significant ECG abnormalities. Known hypersensitivity to study drug or related drugs (e.g. selegiline, MAOA and B inhibitors, or tricyclic antidepressants). Patients treated with potent inhibitors of CYP1A2 or CYP3A4 (a list of such inhibitors will be provided to the investigator). Treatment with MAOA and B inhibitors (including selegiline) within the past 30 days.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>ALS</keyword>
	<keyword>Lou Gehrig's disease</keyword>
</DOC>